Y. Matsuno et al., Predicting the effect of gonadotropin-releasing hormone (GnRH) analogue treatment on uterine leiomyomas based on MR imaging, ACT RADIOL, 40(6), 1999, pp. 656-662
Purpose. To test the hypothesis that the simple assessment of signal intens
ity on T2-weighted MR images is predictive of the effect of hormonal treatm
ent with gonadotropin-releasing hormone (GnRH) analogue.
Material and Methods. The correlation between T2-weighted MR imaging of ute
rine leiomyomas and histologic findings was evaluated using 85 leiomyomas f
rom 62 females who underwent myomectomy or hysterectomy. We also correlated
the pretreatment MR images features obtained in 110 women with 143 leiomyo
mas with the effect of GnRH analogue treatment. The size (length < width x
depth) of the leiomyoma was evaluated before and at 6 months after treatmen
t by ultrasound.
Results. The proportion of leiomyoma cell fascicles and that of extracellul
ar matrix affected signal intensities of uterine leiomyomas on T2-weighted
MR images. The amount of extracellular matrix was predominant in hypointens
e leiomyomas on T2-weighted images, while diffuse intermediate signal leiom
yomas were predominantly composed of leiomyoma cell fascicles. Marked degen
erative changes were noted in leiomyomas with heterogenous hyperintensity.
The homogeneously intermediate signal intensity leiomyomas showed significa
nt size reduction after treatment (size ratio; posttreatment volume/pretrea
tment volume 0.29 +/- 0.11). The size ratio for the hypointense tumors was
0.82 +/- 0.14, and 0.82 +/- 0.18 for the heterogeneously hyperintense tumor
s. There was a significant difference in the response to treatment between
the homogeneously intermediate signal intensity leiomyomas and the hypointe
nse or heterogeneously hyperintense leiomyomas (both p < 0.01).
Conclusion: Signal intensity on T2-weighted MR images depends on the amount
of leiomyoma cell fascicles and extracellular matrix. Simple assessment of
the MR signal intensity is useful in predicting the effect of GnRH analogu
e on uterine leiomyomas.